Altimmune
ALT
43 hedge funds and large institutions have $48.8M invested in Altimmune in 2014 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 2 closing their positions.
350% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 2
35% more call options, than puts
Call options by funds: $58K | Put options by funds: $43K
16% more funds holding
Funds holding: 37 → 43 (+6)
5% more capital invested
Capital invested by funds: $46.4M → $48.8M (+$2.49M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
Top Buyers
Top Sellers
ALT Hedge Fund Activity: Q4 2014 in Review
43 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q4 2014, worth a combined $48.8M — up 5.4% from $46.4M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ALT positions and 2 closed out — a net gain of 7 holders — while 6 added to existing stakes and 8 trimmed.
The largest buyer was Nantahala Capital Management, adding an estimated $1.37M. The largest seller was Perkins Capital Management, cutting an estimated $245K.
- 43 institutional investors held Altimmune (ALT) as of Q4 2014, up from 37 in Q3 2014.
- Funds reported $48.8M of Altimmune stock for Q4 2014, up 5.4% quarter-over-quarter.
- 9 funds opened new Altimmune positions in Q4 2014 and 2 closed out, a net change of +7 holders.
- The largest Altimmune buyer in Q4 2014 was Nantahala Capital Management, an estimated $1.37M added.
- The largest Altimmune seller in Q4 2014 was Perkins Capital Management, an estimated $245K sold.
Based on aggregated 13F filings for Q4 2014.